FIELD: medicine. SUBSTANCE: method involves administering intravenous injection of yeast recombinant inerleykin-2 as durable infusion at a dose of 20 MU and optionally administering intramuscular interferon α injection following the first one. Next to it, when no continuing tumor growth being observed, lymphokin-activated killer cells combined with yeast recombinant inerleykin-2 are intravenously injected as a course. Cytokinetic immunotherapy also optionally includes intravenous administration of yeast recombinant inerleykin-2 in combination with lymphokin-activated killer cells. EFFECT: prolonged patient survival time; reduced number of complications and adverse side effects. 6 cl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING INTRACEREBRAL TUMOR | 2001 |
|
RU2201762C1 |
| METHOD OF DIAGNOSTICS OF INDUCED IMMUNE INFLAMMATION FOCUS IN BRAIN | 1997 |
|
RU2124861C1 |
| METHOD FOR IMMUNOTHERAPY OF CEREBRAL MALIGNANT TUMORS | 2004 |
|
RU2262941C2 |
| METHOD OF IMMUNOTHERAPY MALIGNANT TUMORS OF BRAIN | 2018 |
|
RU2686756C1 |
| METHOD FOR TREATING MALIGNANT BRAIN TUMORS | 2000 |
|
RU2192263C2 |
| METHOD FOR APPLYING COMBINED IMMUNOTHERAPY OF MALIGNANT BRAIN TUMORS | 2000 |
|
RU2197985C2 |
| METHOD OF ADJUVANT IMMUNOTHERAPY OF PRIMARY AND METASTATIC MALIGNANT UNRESECTABLE LIVER TUMOURS | 2006 |
|
RU2326601C2 |
| METHOD OF TREATING UVEAL MELANOMA | 2000 |
|
RU2175242C1 |
| CANCER THERAPY COMBINING LYMPHOEXHAUSTING AGENT WITH CYTOTOXIC LYMPHOCYTES AND CYTOKINES | 2007 |
|
RU2447900C2 |
| SET OF DRUGS FOR CONDUCTING A COURSE OF TERTIARY PREVENTION OF ONCOLOGICAL DISEASES FOR IMMUNOMODULATORY EFFECTS IN COMBINATION THERAPY AND A METHOD FOR TERTIARY PREVENTION OF ONCOLOGICAL DISEASES USING COMBINATION THERAPY USING A SET OF DRUGS FOR IMMUNOMODULATING EFFECTS | 2022 |
|
RU2794024C1 |
